Radiology Business

JUNE 28, 2024

One of the largest radiopharma companies in the world is acquiring global rights to a pair of novel therapeutic and diagnostic drugs used to target a peptide receptor overexpressed in prostate and breast cancers.

Radiopharmaceuticals 86

Radiopharmaceuticals Diagnostic 86

Imaging Technology

SEPTEMBER 20, 2023

a therapeutic oncology company and 3B Pharmaceuticals (3BP) GmbH, a biotechnology company developing targeted radiopharmaceutical drugs and diagnostics for cancer detection and treatment, announced an exclusive licensing agreement for RefleXion to develop and commercialize a specific 3BP molecule to direct its SCINTIX biology-guided radiotherapy.

Pharmaceutical 96

Pharmaceutical Radiopharmaceuticals Radiation Diagnostic 96

Imaging Technology

JANUARY 5, 2024

The PSMA Alpha-PET DoubLET platform technology represents a potential leap forward in the field of prostate cancer diagnostics and treatment. We focused on diagnostic accuracy, patient tolerance and convenience. milla1cf Fri, 01/05/2024 - 11:21 January 5, 2024 — Perspective Therapeutics, Inc.

Radiopharmaceuticals 78

Radiopharmaceuticals Clinic Nuclear Medicine Radiation 78

Imaging Technology

APRIL 5, 2024

milla1cf Fri, 04/05/2024 - 11:31 April 5, 2024 — RLS Radiopharmacies , America’s only Joint Commission-accredited radiopharmacy network, today announced it has expanded its radiopharmaceutical contract development and manufacturing (rCDMO) capabilities by entering into a strategic agreement with global isotope technology leader Eckert & Ziegler.

Radiopharmaceuticals 52

Radiopharmaceuticals Radiation Oncology Radiation Quality and Compliance 52

Imaging Technology

DECEMBER 6, 2023

and Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals, today provided additional information regarding a March 2022 licensing and collaboration agreement between Philochem and Blue Earth Diagnostics.

Diagnostic 96

Diagnostic Diagnostic Imaging Clinic Radiopharmaceuticals 96

Imaging Technology

JUNE 15, 2023

The clinical trial will use this investigational radiopharmaceutical to help understand if patients have CD8+ T cells in their tumors and will, therefore, be more likely to respond to immune checkpoint inhibitors, the main class of immunotherapies currently approved for use.

Radiopharmaceuticals 86

Radiopharmaceuticals Pharmaceutical Nuclear Medicine PET Scan 86

Radiology Business

JULY 14, 2023

The agency issued its solicitation as part of the 2024 Hospital Outpatient Prospective Payment System proposed rule, released late Thursday.

Radiopharmaceuticals 82

Radiopharmaceuticals Diagnostic Hospital IT 82

Diagnostic Imaging

JUNE 28, 2023

discussed the potential impact of urinary activity with positron emission tomography (PET) radiopharmaceuticals, and new phase 3 study data that found low urinary activity with the use of the flotufolastat F 18 injectable agent in patients with prostate cancer.

Radiopharmaceuticals 62

Radiopharmaceuticals Nuclear Medicine Imaging 62

Imaging Technology

JANUARY 5, 2024

milla1cf Fri, 01/05/2024 - 11:32 January 5, 2024 — NorthStar Medical Radioisotopes, LLC , a global innovator in development, production and commercialization of radiopharmaceuticals used to detect and treat cancer and other serious diseases, and Curadh MTR Inc. Chief Executive Officer of NorthStar Medical Radioisotopes.

Radiopharmaceuticals 52

Radiopharmaceuticals Medical Nuclear Medicine Pharmaceutical 52

AuntMinnie

OCTOBER 17, 2023

Blue Earth Diagnostics and Sinotau Pharmaceutical have signed an agreement to distribute Blue Earth's Posluma (flotufolastat F-18) PET radiotracer in China.

Pharmaceutical 52

Pharmaceutical Diagnostic Radiopharmaceuticals 52

Open Medscience

JUNE 22, 2024

Radiotheranostics combines diagnostic imaging and targeted radiotherapy, using radiopharmaceuticals for personalised, precise cancer treatment and improved outcomes. The post What is Radiotheranostics? The Future of Personalised Cancer Diagnosis appeared first on Open MedScience.

Radiopharmaceuticals 52

Radiopharmaceuticals Diagnostic Imaging Diagnostic Imaging 52

Open Medscience

JANUARY 11, 2024

Theranostics merges diagnostics and therapy, revolutionising personalised medicine with genetic profiling and targeted treatment strategies. The post Theranostics Bridging Diagnostics and Therapy for Targeted Treatment appeared first on Open Medscience.

Diagnostic 115

Diagnostic Radiopharmaceuticals Medical Imaging 115

Diagnostic Imaging

JUNE 9, 2024

shared her perspective on a number of topics affecting nuclear medicine, ranging from isotope availability and reimbursement challenges for diagnostic radiopharmaceuticals to increasing patient interest in PET imaging. In a recent interview, Cathy Cutler, Ph.D.,

Nuclear Medicine 70

Nuclear Medicine Radiopharmaceuticals Diagnostic Imaging 70

Open Medscience

JUNE 22, 2024

Radiotheranostic Pairs combine diagnostic imaging with targeted radiotherapy, revolutionising personalised cancer treatment through enhanced precision and efficacy. The post Radiotheranostic Pairs: Bridging Diagnostics and Therapeutics in Cancer appeared first on Open MedScience.

Diagnostic 52

Diagnostic Diagnostic Imaging Imaging Radiopharmaceuticals 52

Imaging Technology

JUNE 10, 2024

For over three decades, Anderson’s pioneering research has laid the foundation for the growth of radiometal-based agents for diagnostic imaging and targeted radionuclide therapy of cancer, a field now known as "theranostics." Louis , Missouri, where she worked more than 20 years developing PET and radiopharmaceutical therapy agents.

Nuclear Medicine 81

Nuclear Medicine Radiopharmaceuticals Disease Imaging 81

Imaging Technology

MAY 30, 2023

milla1cf Tue, 05/30/2023 - 19:49 May 30, 2023 — Blue Earth Diagnostics , a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals , today announced U.S. Chief Executive Officer of Blue Earth Diagnostics. Gauden , D.Phil.,

Diagnostic 74

Diagnostic Imaging Radiopharmaceuticals Diagnostic Imaging 74

Imaging Technology

JUNE 21, 2023

POSLUMA is now commercially available through multiple radiopharmacies of PETNET Solutions, the primary manufacturer and commercial distributor for Blue Earth Diagnostics in the United States. Chief Executive Officer of Blue Earth Diagnostics Ltd. Blue Earth Diagnostics is at Booth 6025 and PETNET Solutions is at Booth 6075.

Diagnostic 74

Diagnostic Radiopharmaceuticals Imaging Medicare 74

ScienceDirect

MARCH 28, 2024

As a classic theranostic radiopharmaceutical, radioiodine (131I) has been utilized in the management of differentiated thyroid cancer (DTC) for more t…

Radiopharmaceuticals 40

Radiopharmaceuticals Diagnostic 40

Imaging Technology

SEPTEMBER 27, 2023

Chief Executive Officer of Blue Earth Diagnostics. Blue Earth Diagnostics will also host an Industry-Expert Theater event, ‘POSLUMA: Precision PET Imaging that is Truly Revealing’.” from October 1 to 4, 2023. Gauden , D.Phil., PET in Patients with Suspected Prostate Cancer Recurrence at PSA Levels Presenter: Ashesh B.

Diagnostic 92

Diagnostic Radiation Oncology Radiation Clinic 92

Diagnostic Imaging

JANUARY 12, 2024

The FDA has accepted Lantheus' abbreviated new drug application for a generic Lutathera, just months after Novartis announced positive phase 3 data supporting a first-line indication for the radiopharmaceutical in neuroendocrine tumors.

Radiopharmaceuticals 127

Radiopharmaceuticals 127

Imaging Technology

JULY 28, 2023

POSLUMA is widely available through 36 radiopharmacies in the national network of Blue Earth Diagnostics’ commercial U.S. The addition of POSLUMA to the highly respected NCCN Guidelines is a major milestone for Blue Earth Diagnostics,” said David E. Chief Medical Officer of Blue Earth Diagnostics. Teoh, MBBS, MRCP, FRCR, D.Phil.,

Clinic 84

Clinic Diagnostic Radiopharmaceuticals Radiation 84

Imaging Technology

JUNE 12, 2024

As president, I will continue to work to support the Facilitating Innovative Nuclear Diagnostics (FIND) Act of 2023 , which will ensure equitable access to care and treatment for patients.” Cutler is a member of the European Association of Nuclear Medicine , the Society of Radiopharmaceutical Sciences , and the American Chemical Association.

Nuclear Medicine 106

Nuclear Medicine Radiopharmaceuticals Education Government 106

AuntMinnie

APRIL 4, 2024

Life Molecular Imaging (LMI) and Sofie Biosciences have begun offering the Neuraceq ( florbetaben F-18) PET radiotracer produced at Sofie's radiopharmaceutical manufacturing site in Cleveland, Ohio. With this expansion, LMI continues driving commercial sales of Neuraceq around the U.S.

Radiopharmaceuticals 95

Radiopharmaceuticals Imaging Disease Diagnostic 95

AuntMinnie

JANUARY 3, 2024

NorthStar Medical Radioisotopes and Chester Springs, PA-based Curadh MTR have entered a strategic collaboration agreement to develop radiopharmaceuticals for the treatment of primary and metastatic solid tumors.

Radiopharmaceuticals 52

Radiopharmaceuticals Diagnostic Clinic Medical 52

Open Medscience

NOVEMBER 9, 2023

The post Unveiling the Complex Etiology and Innovative Diagnostic Approaches in Alzheimer’s Disease appeared first on Open Medscience. Alzheimer's disease stems from genetic mutations and lifestyle factors, leading to brain plaque accumulation and dementia.

Disease 59

Disease Diagnostic Nuclear Medicine Radiopharmaceuticals 59

AuntMinnie

DECEMBER 14, 2023

These folate derivatives will be used for therapeutic and diagnostic applications against folate-receptor-positive malignant tumors such as ovarian cancers. ITM is developing ITM-52, a radiopharmaceutical candidate comprised of a folate receptor α (FRα)-targeting moiety coupled with a medical isotope.

Radiopharmaceuticals 52

Radiopharmaceuticals Clinic Diagnostic Medical 52

AuntMinnie

MAY 17, 2023

The Facilitating Access to Innovative Diagnostics (FIND) Act -- legislatio. Read more on AuntMinnie.com Related Reading: FIND Act reintroduced in Congress MITA hails radiopharmaceutical legislation SNMMI supports new legislation to fix PET payment policy Molecular imaging saw wins, losses over past year

Radiopharmaceuticals 52

Radiopharmaceuticals Diagnostic Imaging 52

AuntMinnie

MAY 1, 2023

Blue Earth Diagnostics is highlighting results from a clinical study that ha. prostate radiopharmaceutical licensing Blue Earth to highlight PET study results at ASTRO Blue Earth wins FDA nod for PSMA-PET tracer NDA

Clinic 52

Clinic Radiopharmaceuticals Diagnostic 52

Imaging Technology

APRIL 24, 2023

milla1cf Mon, 04/24/2023 - 14:10 April 24, 2023 — - NorthStar Medical Radioisotopes , LLC, a global innovator in the development, production and commercialization of radiopharmaceuticals used for therapeutic and medical imaging applications, has announced the appointment of Jean-Noel David , MBA, MS, as Vice President, Operations.

Medical 81

Medical Radiopharmaceuticals Pharmaceutical Government 81

AuntMinnie

JUNE 27, 2023

Blue Earth Diagnostics, a Bracco company, is highlighting results from a stud. prostate radiopharmaceutical licensing

Radiopharmaceuticals 52

Radiopharmaceuticals Diagnostic Clinic Imaging 52

AuntMinnie

MAY 30, 2023

Food and Drug Administration (FDA) has approved Blue Earth Diagnostics. prostate radiopharmaceutical licensing

Radiopharmaceuticals 52

Radiopharmaceuticals Imaging Diagnostic Clinic 52

AuntMinnie

JUNE 20, 2024

To establish which of the two is the optimal first-line approach, the group enrolled 57 patients (63 years old on average; 15 men and 42 women) in a multicenter randomized diagnostic intervention trial. Between November 2019 and May 2022, patients received first-line FCH-PET/CT (n = 29) or MIBI-SPECT/CT (n = 28) prior to surgery.

Radiopharmaceuticals 105

Radiopharmaceuticals Radiation Imaging Clinic 105

AuntMinnie

JUNE 14, 2024

Ben Greenspan, MD, of VA Augusta (GA) Health, said he has never seen a patient harmed by a diagnostic extravasation or infiltration, and the claim that thousands of patients are being injured is "just not right. That might do away with diagnostic concerns, Flannery noted.

Nuclear Medicine 52

Nuclear Medicine Radiation Radiopharmaceuticals Medical 52

Imaging Technology

OCTOBER 11, 2023

based company, to develop, manufacture and commercialize SOFIE’s Gallium-68 and Fluorine-18 labelled diagnostics targeting fibroblast activation protein (FAP). milla1cf Wed, 10/11/2023 - 13:24 October 11, 2023 — GE HealthCare today announced an exclusive global licensing agreement with SOFIE Biosciences (SOFIE), a Virginia, U.S.-based

Healthcare 92

Healthcare Healthcare Pharmaceutical Radiopharmaceuticals 92

Imaging Technology

MAY 14, 2024

Siemens Healthineers and UH will look to also advance the treatment of patients with Alzheimer’s disease and use theranostics—combining the approaches of diagnostics and therapeutics—to treat patients with advanced forms of certain cancers, as well as develop new magnetic resonance ( MR ) technologies.

Hospital 103

Hospital Magnetic Resonance Imaging Radiopharmaceuticals Disease 103

Future Teleradiology

NOVEMBER 27, 2023

Teleradiology-India Introduction: Nuclear medicine continues to be at the forefront of cutting-edge technologies, pushing the boundaries of diagnostic and therapeutic capabilities. Revolutionary Radioisotopes: Expanding the Diagnostic Toolkit: Explore the latest developments in novel radioisotopes used in nuclear medicine.

Nuclear Medicine 52

Nuclear Medicine Radiopharmaceuticals Imaging Modalities Radiation 52

AuntMinnie

MARCH 26, 2024

Food and Drug Administration's (FDA) approvals of radiopharmaceuticals for neuroendocrine tumors and then for prostate cancer, theranostics has picked up momentum in clinical practice, propelled by encouraging research. Since 2013 we've had several more radiopharmaceutical therapies get FDA approval. Since the U.S.

Nuclear Medicine 122

Nuclear Medicine Radiopharmaceuticals Radiation Health Science 122